Necrotizing enterocolitis, or NEC, remains one of the most devastating gastrointestinal emergencies in premature infants, capable of progressing from intestinal inflammation to tissue death, bloodstream infection and multi-organ failure within hours. A new perspective by A. Cuna and V. Sampath in Pediatric Research highlights an intriguing biological strategy that could reshape how scientists think about preventing this disease: carefully tuning the aryl hydrocarbon receptor, a molecular sensor that connects diet, the microbiome and intestinal immune defenses. The article, titled “Harnessing aryl hydrocarbon receptor signaling for NEC: a dish served right,” examines how this pathway might be transformed from a basic cellular mechanism into a therapeutic opportunity.
NEC typically emerges in infants whose intestines are still developing and whose immune systems are not yet prepared to manage the intense microbial exposure that follows birth. Prematurity, formula feeding, abnormal bacterial colonization, impaired blood flow and immature epithelial barriers can combine to trigger an uncontrolled inflammatory response. Instead of maintaining a measured relationship with intestinal microbes, the neonatal gut may activate pathways that damage the very lining meant to protect it. The result can be breakdown of the intestinal barrier, bacterial translocation and an inflammatory cascade involving cytokines such as tumor necrosis factor, interleukin-1β and interleukin-6.
The aryl hydrocarbon receptor, commonly known as AhR, offers a possible control point within this complex system. AhR is a ligand-activated transcription factor expressed by intestinal epithelial cells and multiple immune populations. When a suitable molecule binds to the receptor, AhR partners with the aryl hydrocarbon receptor nuclear translocator, or ARNT, and moves into the cell nucleus. There, the complex binds specific DNA sequences and changes the expression of genes involved in barrier maintenance, detoxification, immune regulation and cellular repair. In the intestine, this signaling network can influence how epithelial cells mature and how immune cells respond to organisms living in the gut.
The receptor’s activity is shaped by a chemically diverse group of ligands. Some originate from dietary components, including compounds generated during the metabolism of vegetables and other plant foods. Others are produced when intestinal bacteria break down tryptophan, an amino acid found in proteins. Microbial metabolites such as indole-3-aldehyde and related indole derivatives can activate AhR, creating a molecular link between the microbiome and host immunity. The pathway can also respond to environmental chemicals and pharmaceuticals, however, which makes therapeutic development more complicated. AhR is not inherently protective or harmful; its effects depend on the ligand, dose, timing and cellular context.
In a healthy intestine, AhR signaling may help strengthen the epithelial barrier and coordinate immune tolerance. It can regulate genes involved in cellular detoxification, including CYP1A1, while supporting communication between epithelial cells and immune populations. AhR activity is also associated with the development and function of innate lymphoid cells, particularly ILC3 cells that can produce interleukin-22. IL-22 acts on epithelial cells and can promote antimicrobial peptide production, mucus generation and tissue repair. These effects are potentially important in premature infants, whose intestinal lining and mucosal defenses are not fully mature when they first encounter a rapidly changing microbial environment.
The promise of the pathway comes with a major scientific challenge: more AhR signaling is not automatically better. Excessive or poorly timed activation could disturb normal development, alter metabolic processes or intensify inflammation under certain conditions. The neonatal intestine is fundamentally different from the adult gut, and a compound that produces a beneficial response in mature animals may behave differently in premature infants. Researchers must therefore determine which ligands activate the protective programs without triggering unwanted toxicological effects. The ideal intervention would be selective, precisely dosed and tailored to the developmental stage of the infant.
The article’s “dish” metaphor points toward one of the most important next steps: testing AhR-directed strategies in controlled laboratory models before they reach the clinic. Human intestinal organoids, sometimes called “mini-guts,” can be grown from stem cells and used to study epithelial development, barrier integrity and inflammatory responses. When combined with immune cells, bacterial products or carefully designed microbial communities, these systems may reveal how premature intestinal tissue responds to specific AhR ligands. Measurements of electrical barrier resistance, tight-junction proteins, cytokine release, epithelial cell death and microbial passage could help identify compounds that genuinely protect the gut rather than merely suppress visible inflammation.
Animal studies and ultimately clinical research will also need to address the realities of neonatal care. Any candidate therapy must be compatible with breast milk, donor milk, fortifiers, antibiotics and other treatments commonly used in neonatal intensive care units. It must remain stable in the infant gut, reach the appropriate cells and avoid disrupting beneficial microbial colonization. Investigators will also need biomarkers that show whether the pathway is being activated safely. Levels of microbial indole metabolites, expression of AhR-responsive genes, intestinal cytokine profiles and patterns of bacterial colonization could potentially guide treatment and identify infants most likely to benefit.
For now, the work represents a forward-looking framework rather than a ready-made cure for NEC. Its central message is that the infant intestine may be protected not only by suppressing inflammation after injury begins, but by restoring the molecular conversations among microbes, epithelial cells and the immune system before the disease gains momentum. By treating AhR as a finely adjustable biological circuit instead of a simple on-or-off switch, researchers may be able to develop interventions that reinforce the premature gut’s natural defenses. The strategy will require rigorous testing, but it offers a compelling direction in the search for safer ways to prevent one of neonatology’s most urgent diseases.
Subject of Research: Harnessing aryl hydrocarbon receptor signaling as a potential strategy for preventing or treating necrotizing enterocolitis in premature infants.
Article Title: Harnessing aryl hydrocarbon receptor signaling for NEC: a dish served right
Article References: Cuna, A., Sampath, V. “Harnessing aryl hydrocarbon receptor signaling for NEC: a dish served right.” Pediatric Research (2026). https://doi.org/10.1038/s41390-026-05293-w
Image Credits: AI Generated
DOI: https://doi.org/10.1038/s41390-026-05293-w
Keywords: Necrotizing enterocolitis, premature infants, aryl hydrocarbon receptor, AhR signaling, neonatal intestinal inflammation, gut barrier, microbiome, intestinal organoids, IL-22, neonatal medicine
